← Leaderboards
Bradley Wertheim
Brigham And Women'S Hospital
$1,908,343
Attributed
$1,908,343
Total exposure
3
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $932.4K · FY2020–25$1M$750K$500K$250K$0
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$1,908,343 · 3
By mechanism
K08$844,411 · 1
R01$800,962 · 1
R03$262,970 · 1
Top collaborators
No co-investigators on record.
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- Bradley Maron$8,442,424
- John P Forman$11,830,902
- Howard D Sesso$5,697,818
- Laura Elizabeth Fredenburgh$4,191,382
- Stephen Y Chan$16,563,292
Others in their field
Other Emerging Leaders on “Pathway Analysis”
- Mathangi Thiagarajan · Leidos Biomedical Research, Inc.$37,695,154
- Priyamvada Acharya · Duke University$20,941,151
- Ashlin Bolton · Broad Institute, Inc.$19,699,069
- Leigh A Johnson · University Of North Texas Hlth Sci Ctr$14,236,023
- Bjorn E Oskarsson · Mayo Clinic Jacksonville$11,846,278
- Abraham Aizer Brody · New York University School Of Medicine$11,132,986
Research focus
Pathway AnalysisPreventMonocrotalineOverexpressionMolecularPhenotypeMedicineFunctional DisorderHeart FailureMortalityInflammatoryImpairmentCellsIn VitroEndothelial DysfunctionIn VivoEndotheliumFibrosisArteriesCollagenHypoxiaLungCessation Of LifeProgressive Disease
Grant awards (8)
Endothelial Inflammation, Src Kinase Dysregulation, and Fibrosis in Early Pulmonary Arterial Hypertension$800,962
R01 · FY2025 · HL · contact PI
Endothelial Proline Utilization in Pulmonary Arterial Hypertension$131,485
R03 · FY2025 · HL · contact PI
Ubiquitination and Endothelial Fibrosis in Early Pulmonary Arterial Hypertension$168,952
K08 · FY2024 · HL · contact PI
Endothelial Proline Utilization in Pulmonary Arterial Hypertension$131,485
R03 · FY2024 · HL · contact PI
Ubiquitination and Endothelial Fibrosis in Early Pulmonary Arterial Hypertension$168,952
K08 · FY2023 · HL · contact PI
Ubiquitination and Endothelial Fibrosis in Early Pulmonary Arterial Hypertension$168,952
K08 · FY2022 · HL · contact PI
Ubiquitination and Endothelial Fibrosis in Early Pulmonary Arterial Hypertension$168,859
K08 · FY2021 · HL · contact PI
Ubiquitination and Endothelial Fibrosis in Early Pulmonary Arterial Hypertension$168,696
K08 · FY2020 · HL · contact PI